Search

Your search keyword '"Sherman, Amy C"' showing total 170 results
Start Over Author "Sherman, Amy C"
170 results on '"Sherman, Amy C"'

1. IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition

Author

Ozonoff, Al, Ehrlich, Lauren IR, Melamed, Esther, Sesma, Ana Fernandez, Simon, Viviana, Pulendran, Bali, Nadeau, Kari C, Davis, Mark M, McCoey, Grace A, Sekaly, Rafick, Baden, Lindsey R, Levy, Ofer, Schaenman, Joanna, Reed, Elaine F, Shaw, Albert C, Hafler, David A, Montgomery, Ruth R, Kleinstein, Steven H, Becker, Patrice M, Augustine, Alison D, Calfee, Carolyn S, Erle, David J, DeBakey, Michael E, Corry, David B, Kheradmand, Farrah, Atkinson, Mark A, Brakenridge, Scott C, Higuita, Nelson I Agudelo, Metcalf, Jordan P, Hough, Catherine L, Messer, William B, Kraft, Monica, Bime, Chris, Peters, Bjoern, Milliren, Carly E, Syphurs, Caitlin, McEnaney, Kerry, Barton, Brenda, Lentucci, Claudia, Saluvan, Mehmet, Chang, Ana C, Hoch, Annmarie, Albert, Marisa, Shaheen, Tanzia, Kho, Alvin T, Liu, Shanshan, Thomas, Sanya, Chen, Jing, Murphy, Maimouna D, Cooney, Mitchell, Hayati, Arash Nemati, Bryant, Robert, Abraham, James, Jayavelu, Naresh Doni, Presnell, Scott, Jancsyk, Tomasz, Maguire, Cole, Qi, Jingjing, Lee, Brian, Fourati, Slim, Esserman, Denise A, Guan, Leying, Gygi, Jeremy, Pawar, Shrikant, Brito, Anderson, Fragiadakis, Gabriela K, Patel, Ravi, Overton, James A, Vita, Randi, Westendorf, Kerstin, Shannon, Casey P, Tebbutt, Scott J, Thyagarajan, Rama V, Rousseau, Justin F, Wylie, Dennis, Triplett, Todd A, Kojic, Erna, Chinthrajah, Sharon, Ahuja, Neera, Rogers, Angela J, Artandi, Maja, Geng, Linda, Yendewa, George, Powell, Debra L, Kim, James N, Simmons, Brent, Goonewardene, I Michael, Smith, Cecilia M, Martens, Mark, Sherman, Amy C, Walsh, Stephen R, Issa, Nicolas C, Salehi-Rad, Ramin, Dela Cruz, Charles, Farhadian, Shelli, Iwasaki, Akiko, Ko, Albert I, Anderson, Evan J, Mehta, Aneesh K, and Sevransky, Jonathan E

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Immunology, Infectious Diseases, Coronaviruses, Lung, Emerging Infectious Diseases, Inflammatory and immune system, Good Health and Well Being, Humans, COVID-19, Glycosylation, SARS-CoV-2, Glycosyltransferases, Complement System Proteins, Immunoglobulin M, IMPACC Network
Abstract

The glycosylation of IgG plays a critical role during human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during human acute viral infection. The analysis of IgM N-glycosylation from healthy controls and hospitalized coronavirus disease 2019 (COVID-19) patients reveals increased high-mannose and sialylation that correlates with COVID-19 severity. These trends are confirmed within SARS-CoV-2-specific immunoglobulin N-glycan profiles. Moreover, the degree of total IgM mannosylation and sialylation correlate significantly with markers of disease severity. We link the changes of IgM N-glycosylation with the expression of Golgi glycosyltransferases. Lastly, we observe antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients and modulated by exoglycosidase digestion. Taken together, this work links the IgM N-glycosylation with COVID-19 severity and highlights the need to understand IgM glycosylation and downstream immune function during human disease.

Published
2024

2. Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study

Author

McEnaney, Kerry, Barton, Brenda, Lentucci, Claudia, Saluvan, Mehmet, Chang, Ana C, Hoch, Annmarie, Albert, Marisa, Shaheen, Tanzia, Kho, Alvin T, Thomas, Sanya, Chen, Jing, Murphy, Maimouna D, Cooney, Mitchell, Hayati, Arash Nemati, Bryant, Robert, Abraham, James, Presnell, Scott, Jancsyk, Tomasz, Maguire, Cole, Lee, Brian, Fourati, Slim, Esserman, Denise A, Guan, Leying, Gygi, Jeremy, Pawar, Shrikant, Brito, Anderson, Fragiadakis, Gabriela K, Patel, Ravi, Tebbutt, Scott J, Overton, James A, Vita, Randi, Westendorf, Kerstin, Thyagarajan, Rama V, Rousseau, Justin F, Wylie, Dennis, Triplett, Todd A, Kojic, Erna, Chinthrajah, Sharon, Ahuja, Neera, Rogers, Angela J, Artandi, Maja, Yendewa, George, Powell, Debra L, Kim, James N, Simmons, Brent, Goonewardene, I Michael, Smith, Cecilia M, Martens, Mark, Sherman, Amy C, Walsh, Stephen R, Issa, Nicolas C, Salehi-Rad, Ramin, Dela Cruz, Charles, Farhadian, Shelli, Iwasaki, Akiko, Ko, Albert I, Anderson, Evan J, Mehta, Aneesh K, Sevransky, Jonathan E, Leligdowicz, Aleksandra, Matthay, Michael A, Singer, Jonathan P, Kangelaris, Kirsten N, Hendrickson, Carolyn M, Krummel, Matthew F, Woodruff, Prescott G, Anderson, Matthew L, Guirgis, Faheem W, Drevets, Douglas A, Brown, Brent R, Siegel, Sarah AR, Lu, Zhengchun, Mosier, Jarrod, Kimura, Hiroki, Khor, Bernard, Rahman, Adeeb, Stadlbauer, Daniel, Dutta, Jayeeta, Gonzalez-Reiche, Ana Silvia, van de Guchte, Adriana, Carreño, Juan Manuel, Singh, Gagandeep, Raskin, Ariel, Tcheou, Johnstone, Bielak, Dominika, Kawabata, Hisaaki, Xie, Hui, Kelly, Geoffrey, Patel, Manishkumar, Nie, Kai, Yellin, Temima, Fried, Miriam, Sullivan, Leeba, Morris, Sara, Sieg, Scott, van Zalm, Patrick, Fatou, Benoit, Mendez, Kevin, Lasky-Su, Jessica, and Hutton, Scott R

Subjects
Health Services and Systems, Biomedical and Clinical Sciences, Health Sciences, Prevention, Vaccine Related, Emerging Infectious Diseases, Biodefense, Brain Disorders, Infectious Diseases, Lung, Good Health and Well Being, Female, Humans, SARS-CoV-2, COVID-19, B-Lymphocytes, Body Fluids, Disease Progression, Phenotype, IMPACC Network
Abstract

Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year after discharge. Modeling identified 4 PRO clusters based on reported deficits (minimal, physical, mental/cognitive, and multidomain), supporting heterogenous clinical presentations in PASC, with sub-phenotypes associated with female sex and distinctive comorbidities. During the acute phase of disease, a higher respiratory SARS-CoV-2 viral burden and lower Receptor Binding Domain and Spike antibody titers were associated with both the physical predominant and the multidomain deficit clusters. A lower frequency of circulating B lymphocytes by mass cytometry (CyTOF) was observed in the multidomain deficit cluster. Circulating fibroblast growth factor 21 (FGF21) was significantly elevated in the mental/cognitive predominant and the multidomain clusters. Future efforts to link PASC to acute anti-viral host responses may help to better target treatment and prevention of PASC.

Published
2024

3. Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series

Author

Sherman, Amy C., van Haren, Simon D., Borberg, Ella, Swank, Zoe, Aleissa, Muneerah, Tong, Alexandra, Rooks, Rebecca, Kanwal, Urwah, Levine, Hannah, Yates, Bridget, Izaguirre, Natalie, Ryff, Kevin, Thomas, Sanya, Parisi, Lindsey, Li, Xiaofang, Walt, David R., Levy, Ofer, Walsh, Stephen R., Issa, Nicolas C., and Baden, Lindsey R.

Published
2024
Full Text
View/download PDF

4. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Author

Branche, Angela R., Rouphael, Nadine G., Diemert, David J., Falsey, Ann R., Losada, Cecilia, Baden, Lindsey R., Frey, Sharon E., Whitaker, Jennifer A., Little, Susan J., Anderson, Evan J., Walter, Emmanuel B., Novak, Richard M., Rupp, Richard, Jackson, Lisa A., Babu, Tara M., Kottkamp, Angelica C., Luetkemeyer, Anne F., Immergluck, Lilly C., Presti, Rachel M., Bäcker, Martín, Winokur, Patricia L., Mahgoub, Siham M., Goepfert, Paul A., Fusco, Dahlene N., Malkin, Elissa, Bethony, Jeffrey M., Walsh, Edward E., Graciaa, Daniel S., Samaha, Hady, Sherman, Amy C., Walsh, Stephen R., Abate, Getahun, Oikonomopoulou, Zacharoula, El Sahly, Hana M., Martin, Thomas C. S., Kamidani, Satoshi, Smith, Michael J., Ladner, Benjamin G., Porterfield, Laura, Dunstan, Maya, Wald, Anna, Davis, Tamia, Atmar, Robert L., Mulligan, Mark J., Lyke, Kirsten E., Posavad, Christine M., Meagher, Megan A., Stephens, David S., Neuzil, Kathleen M., Abebe, Kuleni, Hill, Heather, Albert, Jim, Telu, Kalyani, Mu, Jinjian, Lewis, Teri C., Giebeig, Lisa A., Eaton, Amanda, Netzl, Antonia, Wilks, Samuel H., Türeli, Sina, Makhene, Mamodikoe, Crandon, Sonja, Montefiori, David C., Makowski, Mat, Smith, Derek J., Nayak, Seema U., Roberts, Paul C., and Beigel, John H.

Published
2023
Full Text
View/download PDF

5. COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva

Author

Randad, Pranay R, Pisanic, Nora, Kruczynski, Kate, Manabe, Yukari C, Thomas, David, Pekosz, Andrew, Klein, Sabra L, Betenbaugh, Michael J, Clarke, William A, Laeyendecker, Oliver, Caturegli, Patrizio P, Larman, H Benjamin, Detrick, Barbara, Fairley, Jessica K, Sherman, Amy C, Rouphael, Nadine, Edupuganti, Srilatha, Granger, Douglas A, Granger, Steve W, Collins, Matthew, and Heaney, Christopher D

Subjects
SARS-CoV-2, COVID-19, saliva, oral fluid, serology, antibody test, multiplex, diagnostics, immunoserology, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Microbiology
Published
2021

6. Immunogenicity of quadrivalent meningococcal conjugate vaccine in frequent platelet donors

Author

Desjardins, Michaël, Cunningham, Phoebe, Mitre, Xhoi, Pierre, Djenane, Montesano, Christina, Woods, Tenaizus, Oganezova, Karina, Krauss, Jonathan H., Von, Salena S., Kupelian, John A., Li, Xiaofang, Gothing, Jon A., Kleinjan, Jane A., Zhou, Guohai, Piantadosi, Steven, Sherman, Amy C., Walsh, Stephen R., Issa, Nicolas C., Kaufman, Richard M., and Baden, Lindsey R.

Published
2023
Full Text
View/download PDF

8. COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva.

Author

Pisanic, Nora, Randad, Pranay R, Kruczynski, Kate, Manabe, Yukari C, Thomas, David L, Pekosz, Andrew, Klein, Sabra L, Betenbaugh, Michael J, Clarke, William A, Laeyendecker, Oliver, Caturegli, Patrizio P, Larman, H Benjamin, Detrick, Barbara, Fairley, Jessica K, Sherman, Amy C, Rouphael, Nadine, Edupuganti, Srilatha, Granger, Douglas A, Granger, Steve W, Collins, Matthew H, and Heaney, Christopher D

Subjects
Saliva, Humans, Immunoglobulin A, Immunoglobulin G, Immunoglobulin M, Antibodies, Viral, Female, Male, Spike Glycoprotein, Coronavirus, COVID-19, SARS-CoV-2, COVID-19 Nucleic Acid Testing, Coronavirus Nucleocapsid Proteins, antibody test, diagnostics, immunoserology, multiplex, oral fluid, saliva, serology, Antibodies, Viral, Spike Glycoprotein, Coronavirus, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Microbiology
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of an ongoing pandemic that has infected over 36 million and killed over 1 million people. Informed implementation of government public health policies depends on accurate data on SARS-CoV-2 immunity at a population scale. We hypothesized that detection of SARS-CoV-2 salivary antibodies could serve as a noninvasive alternative to serological testing for monitoring of SARS-CoV-2 infection and seropositivity at a population scale. We developed a multiplex SARS-CoV-2 antibody immunoassay based on Luminex technology that comprised 12 CoV antigens, mostly derived from SARS-CoV-2 nucleocapsid (N) and spike (S). Saliva and sera collected from confirmed coronavirus disease 2019 (COVID-19) cases and from the pre-COVID-19 era were tested for IgG, IgA, and IgM to the antigen panel. Matched saliva and serum IgG responses (n = 28) were significantly correlated. The salivary anti-N IgG response resulted in the highest sensitivity (100%), exhibiting a positive response in 24/24 reverse transcription-PCR (RT-PCR)-confirmed COVID-19 cases sampled at >14 days post-symptom onset (DPSO), whereas the salivary anti-receptor binding domain (RBD) IgG response yielded 100% specificity. Temporal kinetics of IgG in saliva were consistent with those observed in blood and indicated that most individuals seroconvert at around 10 DPSO. Algorithms employing a combination of the IgG responses to N and S antigens result in high diagnostic accuracy (100%) by as early as 10 DPSO. These results support the use of saliva-based antibody testing as a noninvasive and scalable alternative to blood-based antibody testing.

Published
2020

10. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study

Author

Ozonoff, Al, Schaenman, Joanna, Jayavelu, Naresh Doni, Milliren, Carly E., Calfee, Carolyn S., Cairns, Charles B., Kraft, Monica, Baden, Lindsey R., Shaw, Albert C., Krammer, Florian, van Bakel, Harm, Esserman, Denise A., Liu, Shanshan, Sesma, Ana Fernandez, Simon, Viviana, Hafler, David A., Montgomery, Ruth R., Kleinstein, Steven H., Levy, Ofer, Bime, Chris, Haddad, Elias K., Erle, David J., Pulendran, Bali, Nadeau, Kari C., Davis, Mark M, Hough, Catherine L., Messer, William B., Higuita, Nelson I. Agudelo, Metcalf, Jordan P., Atkinson, Mark A., Brakenridge, Scott C., Corry, David, Kheradmand, Farrah, Ehrlich, Lauren I.R., Melamed, Esther, McComsey, Grace A., Sekaly, Rafick, Diray-Arce, Joann, Peters, Bjoern, Augustine, Alison D., Reed, Elaine F., McEnaney, Kerry, Barton, Brenda, Lentucci, Claudia, Saluvan, Mehmet, Chang, Ana C., Hoch, Annmarie, Albert, Marisa, Shaheen, Tanzia, Kho, Alvin T., Thomas, Sanya, Chen, Jing, Murphy, Maimouna D., Cooney, Mitchell, Presnell, Scott, Fragiadakis, Gabriela K., Patel, Ravi, Guan, Leying, Gygi, Jeremy, Pawar, Shrikant, Brito, Anderson, Khalil, Zain, Maguire, Cole, Fourati, Slim, Overton, James A., Vita, Randi, Westendorf, Kerstin, Salehi-Rad, Ramin, Leligdowicz, Aleksandra, Matthay, Michael A., Singer, Jonathan P., Kangelaris, Kirsten N., Hendrickson, Carolyn M., Krummel, Matthew F., Langelier, Charles R., Woodruff, Prescott G., Powell, Debra L., Kim, James N., Simmons, Brent, Goonewardene, I. Michael, Smith, Cecilia M., Martens, Mark, Mosier, Jarrod, Kimura, Hiroki, Sherman, Amy C., Walsh, Stephen R., Issa, Nicolas C., Dela Cruz, Charles, Farhadian, Shelli, Iwasaki, Akiko, Ko, Albert I., Chinthrajah, Sharon, Ahuja, Neera, Rogers, Angela J., Artandi, Maja, Siegel, Sarah A.R., Lu, Zhengchun, Drevets, Douglas A., Brown, Brent R., Anderson, Matthew L., Guirgis, Faheem W., Thyagarajan, Rama V., Rousseau, Justin F., Wylie, Dennis, Busch, Johanna, Gandhi, Saurin, Triplett, Todd A., Yendewa, George, Giddings, Olivia, Anderson, Evan J., Mehta, Aneesh K., Sevransky, Jonathan E., Khor, Bernard, Rahman, Adeeb, Stadlbauer, Daniel, Dutta, Jayeeta, Xie, Hui, Kim-Schulze, Seunghee, Gonzalez-Reiche, Ana Silvia, van de Guchte, Adriana, Farrugia, Keith, Khan, Zenab, Maecker, Holden T., Elashoff, David, Brook, Jenny, Ramires-Sanchez, Estefania, Llamas, Megan, Rivera, Adreanne, Perdomo, Claudia, Ward, Dawn C., Magyar, Clara E., Fulcher, Jennifer A., Abe-Jones, Yumiko, Asthana, Saurabh, Beagle, Alexander, Bhide, Sharvari, Carrillo, Sidney A., Chak, Suzanna, Ghale, Rajani, Gonzalez, Ana, Jauregui, Alejandra, Jones, Norman, Lea, Tasha, Lee, Deanna, Lota, Raphael, Milush, Jeff, Nguyen, Viet, Pierce, Logan, Prasad, Priya A., Rao, Arjun, Samad, Bushra, Shaw, Cole, Sigman, Austin, Sinha, Pratik, Ward, Alyssa, Willmore, Andrew, Zhan, Jenny, Rashid, Sadeed, Rodriguez, Nicklaus, Tang, Kevin, Altamirano, Luz Torres, Betancourt, Legna, Curiel, Cindy, Sutter, Nicole, Paz, Maria Tercero, Tietje-Ulrich, Gayelan, Leroux, Carolyn, Connors, Jennifer, Bernui, Mariana, Kutzler, Michel A., Edwards, Carolyn, Lee, Edward, Lin, Edward, Croen, Brett, Semenza, Nicholas C., Rogowski, Brandon, Melnyk, Nataliya, Woloszczuk, Kyra, Cusimano, Gina, Bell, Mathew R., Furukawa, Sara, McLin, Renee, Marrero, Pamela, Sheidy, Julie, Tegos, George P., Nagle, Crystal, Mege, Nathan, Ulring, Kristen, Seyfert-Margolis, Vicki, Conway, Michelle, Francisco, Dave, Molzahn, Allyson, Erickson, Heidi, Wilson, Connie Cathleen, Schunk, Ron, Sierra, Bianca, Hughes, Trina, Smolen, Kinga, Desjardins, Michael, van Haren, Simon, Mitre, Xhoi, Cauley, Jessica, Li, Xiaofang, Tong, Alexandra, Evans, Bethany, Montesano, Christina, Licona, Jose Humberto, Krauss, Jonathan, Chang, Jun Bai Park, Izaguirre, Natalie, Chaudhary, Omkar, Coppi, Andreas, Fournier, John, Mohanty, Subhasis, Muenker, M. Catherine, Nelson, Allison, Raddassi, Khadir, Rainone, Michael, Ruff, William E., Salahuddin, Syim, Schulz, Wade L., Vijayakumar, Pavithra, Wang, Haowei, Wunder Jr., Elsio, Young, H. Patrick, Zhao, Yujiao, Saksena, Miti, Altman, Deena, Kojic, Erna, Srivastava, Komal, Eaker, Lily Q., Bermúdez-González, Maria C., Beach, Katherine F., Sominsky, Levy A., Azad, Arman R., Carreño, Juan Manuel, Singh, Gagandeep, Raskin, Ariel, Tcheou, Johnstone, Bielak, Dominika, Kawabata, Hisaaki, Mulder, Lubbertus CF, Kleiner, Giulio, Lee, Alexandra S., Do, Evan Do, Fernandes, Andrea, Manohar, Monali, Hagan, Thomas, Blish, Catherine A., Din, Hena Naz, Roque, Jonasel, Yang, Samuel, Brunton, Amanda, Sullivan, Peter E., Strnad, Matthew, Lyski, Zoe L., Coulter, Felicity J., Booth, J. Leland, Sinko, Lauren A., Moldawer, Lyle L., Borresen, Brittany, Roth-Manning, Brittney, Song, Li-Zhen, Nelson, Ebony, Lewis-Smith, Megan, Smith, Jacob, Tipan, Pablo Guaman, Siles, Nadia, Bazzi, Sam, Geltman, Janelle, Hurley, Kerin, Gabriele, Gio, Sieg, Scott, Vaysman, Tatyana, Bristow, Laurel, Hussaini, Laila, Hellmeister, Kieffer, Samaha, Hady, Cheng, Andrew, Spainhour, Christine, Scherer, Erin M., Johnson, Brandi, Bechnak, Amer, Ciric, Caroline R., Hewitt, Lauren, Carter, Erin, Mcnair, Nina, Panganiban, Bernadine, Huerta, Christopher, Usher, Jacob, Ribeiro, Susan Pereira, Altman, Matthew C., Becker, Patrice M., Rouphael, Nadine, Bime, Christian, and Davis, Mark M.

Published
2022
Full Text
View/download PDF

11. COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials.

Author

Sherman, Amy C, Tuan, Jessica, Cantos, Valeria D, Adeyiga, Oladunni, Mahoney, Scott, Ortega-Villa, Ana M, Tillman, Amy, Whitaker, Jennifer, Davis, Amanda S Woodward, Leav, Brett, Hirsch, Ian, Sadoff, Jerald, Dunkle, Lisa M, Gilbert, Peter B, Janes, Holly E, Kublin, James G, Goepfert, Paul A, Kotloff, Karen, Rouphael, Nadine, and Falsey, Ann R

Subjects
*NUTRITION disorders, *PLACEBOS, *VACCINE effectiveness, *IMMUNOCOMPROMISED patients, *STATISTICAL sampling, *IMMUNE system, *COVID-19 vaccines, *RANDOMIZED controlled trials, *PHARMACEUTICAL industry
Abstract

Background Although the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are highly efficacious at preventing severe disease in the general population, current data are lacking regarding vaccine efficacy (VE) for individuals with mild immunocompromising conditions. Methods A post hoc, cross-protocol analysis of participant-level data from the blinded phase of four randomized, placebo-controlled, coronavirus disease 2019 (COVID-19) vaccine phase 3 trials (Moderna, AstraZeneca, Janssen, and Novavax) was performed. We defined a "tempered immune system" (TIS) variable via a consensus panel based on medical history and medications to determine VE against symptomatic and severe COVID-19 cases in TIS participants versus non-TIS individuals starting at 14 days after completion of the primary series through the blinded phase for each of the 4 trials. An analysis of participants living with well-controlled human immunodeficiency virus was conducted using the same methods. Results A total of 3852/30 351 (12.7%) Moderna participants, 3088/29 868 (10.3%) Novavax participants, 3549/32 380 (11.0%) AstraZeneca participants, and 5047/43 788 (11.5%) Janssen participants were identified as having a TIS. Most TIS conditions (73.9%) were due to metabolism and nutritional disorders. Vaccination (vs placebo) significantly reduced the likelihood of symptomatic and severe COVID-19 for all participants for each trial. VE was not significantly different for TIS participants versus non-TIS for either symptomatic or severe COVID-19 for each trial, nor was VE significantly different in the symptomatic endpoint for participants with human immunodeficiency virus. Conclusions For individuals with mildly immunocompromising conditions, there is no evidence of differences in VE against symptomatic or severe COVID-19 compared with those with non-TIS in the 4 COVID-19 vaccine randomized controlled efficacy trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults

Author

Rostad, Christina A, primary, Atmar, Robert L, additional, Walter, Emmanuel B, additional, Frey, Sharon, additional, Meier, Jeffery L, additional, Sherman, Amy C, additional, Lai, Lilin, additional, Tsong, Rachel, additional, Kao, Carol M, additional, Raabe, Vanessa, additional, El Sahly, Hana M, additional, Keitel, Wendy A, additional, Whitaker, Jennifer A, additional, Smith, Michael J, additional, Schmader, Kenneth E, additional, Swamy, Geeta K, additional, Abate, Getahun, additional, Winokur, Patricia, additional, Buchanan, Wendy, additional, Cross, Kaitlyn, additional, Wegel, Ashley, additional, Xu, Yongxian, additional, Yildirim, Inci, additional, Kamidani, Satoshi, additional, Rouphael, Nadine, additional, Roberts, Paul C, additional, Mulligan, Mark J, additional, and Anderson, Evan J, additional

Published
2024
Full Text
View/download PDF

14. Neuroinvasive Bacillus cereus Infection in Immunocompromised Hosts: Epidemiologic Investigation of 5 Patients With Acute Myeloid Leukemia

Author

Little, Jessica S, primary, Coughlin, Cassie, additional, Hsieh, Candace, additional, Lanza, Meaghan, additional, Huang, Wan Yi, additional, Kumar, Aishwarya, additional, Dandawate, Tanvi, additional, Tucker, Robert, additional, Gable, Paige, additional, Vazquez Deida, Axel A, additional, Moulton-Meissner, Heather, additional, Stevens, Valerie, additional, McAllister, Gillian, additional, Ewing, Thomas, additional, Diaz, Maria, additional, Glowicz, Janet, additional, Winkler, Marisa L, additional, Pecora, Nicole, additional, Kubiak, David W, additional, Pearson, Jeffrey C, additional, Luskin, Marlise R, additional, Sherman, Amy C, additional, Woolley, Ann E, additional, Brandeburg, Christina, additional, Bolstorff, Barbara, additional, McHale, Eileen, additional, Fortes, Esther, additional, Doucette, Matthew, additional, Smole, Sandra, additional, Bunnell, Craig, additional, Gross, Anne, additional, Platt, Dana, additional, Desai, Sonali, additional, Fiumara, Karen, additional, Issa, Nicolas C, additional, Baden, Lindsey R, additional, Rhee, Chanu, additional, Klompas, Michael, additional, and Baker, Meghan A, additional

Published
2024
Full Text
View/download PDF

15. 2707. Complications of Babesiosis in Immunocompromised and Asplenic/Hyposplenic Patients

Author

Harris, Courtney E, primary, Kakoullis, Loukas, additional, Aleissa, Muneerah M, additional, Haddad, Esther Arbona, additional, Kim, Andy J, additional, Rooks, Rebecca, additional, Yates, Bridget, additional, Kanwal, Urwah, additional, Izaguirre, Natalie E, additional, Little, Jessica S, additional, Hammond, Sarah P, additional, Montgomery, Mary W, additional, Sherman, Amy C, additional, Maguire, James, additional, Woolley, Ann E, additional, Baden, Lindsey R, additional, and Issa, Nicolas C, additional

Published
2023
Full Text
View/download PDF

16. 2714. Invasive Fungal Disease in Lung Transplant Recipients: Incidence, Risk Factors, and Outcomes

Author

Kovac, Victor, primary, Goldberg, Hilary J, additional, Kim, Andy J, additional, Joyce, Mary-Ruth M, additional, Mallidi, Hari R, additional, Coppolino, Antonio, additional, Townsend, Keri, additional, Thaniyavarn, Tany, additional, Kennedy, John C, additional, Lee, Stefi F, additional, Durney, Valerie, additional, Liakos, Alexis, additional, Harris, Courtney E, additional, Little, Jessica S, additional, Sherman, Amy C, additional, Issa, Nicolas C, additional, Baden, Lindsey R, additional, Sharma, Nirmal S, additional, and Woolley, Ann E, additional

Published
2023
Full Text
View/download PDF

18. SARS-CoV-2 Vaccine Non-response among Hematopoietic Stem Cell Transplant Patients: A Systematic Review and Meta-analysis

Author

Kokogho, Afoke, primary, Crowell, Trevor A., additional, Bain, Paul A., additional, Popal, Sudaba, additional, Aleissa, Muneerah, additional, Chang, Jun Bai Park, additional, Aleissa, Deema, additional, Osamade, Agho, additional, Novack, Lewis A., additional, Heithoff, August, additional, Baden, Lindsey R., additional, Sherman, Amy C., additional, and Walsh, Stephen R., additional

Published
2023
Full Text
View/download PDF

19. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients

Author

Aleissa, Muneerah M., primary, Little, Jessica S., additional, Davey, Sonya, additional, Saucier, Anna, additional, Zhou, Guohai, additional, Gonzalez-Bocco, Isabel H., additional, Crombie, Jennifer L., additional, Looka, Andrew, additional, Baden, Lindsey R., additional, Issa, Nicolas C., additional, Hammond, Sarah P., additional, Jacobson, Caron A., additional, and Sherman, Amy C., additional

Published
2023
Full Text
View/download PDF

21. SARS-CoV-2 Vaccine-Induced Immune Responses Among Hematopoietic Stem Cell Transplant Recipients.

Author

Kokogho, Afoke, Crowell, Trevor A, Aleissa, Muneerah, Lupan, Ana-Mihaela, Davey, Sonya, Chang, Jun Bai Park, Baden, Lindsey R, Walsh, Stephen R, and Sherman, Amy C

Subjects
SARS-CoV-2, STEM cell transplantation, HEMATOPOIETIC stem cells, HEMATOPOIETIC stem cell transplantation, COVID-19
Abstract

Background Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination reduces the risk and severity of coronavirus disease 2019 (COVID-19), several variables may impact the humoral response among patients undergoing hematopoietic stem cell transplantation (HSCT). Methods A retrospective chart review was conducted among SARS-CoV-2-vaccinated HSCT recipients between 2020 and 2022 at a single center in Boston, Massachusetts. Patients age ≥18 years who received doses of Pfizer, Moderna, or J&J vaccines were included. Anti-spike (S) immunoglobulin G (IgG) titer levels were measured using the Roche assay. Responders (≥0.8 U/mL) and nonresponders (<0.8 U/mL) were categorized and analyzed. Multivariable linear and logistic regression were used to estimate the correlation coefficient and odds ratio of response magnitude and status. Results Of 152 HSCT recipients, 141 (92.8%) were responders, with a median (interquartile range [IQR]) anti-S IgG titer of 2500 (107.9–2500) U/mL at a median (IQR) of 80.5 (36–153.5) days from last dose, regardless of the number of doses received. Higher quantitative titers were associated with receipt of more vaccine doses (coeff, 205.79; 95% CI, 30.10 to 381.47; P =.022), being female (coeff, 343.5; 95% CI, −682.6 to −4.4; P =.047), being younger (<65 years; coeff, 365.2; 95% CI, −711.3 to 19.1; P =.039), and not being on anti-CD20 therapy (coeff, −1163.7; 95% CI, −1717.7 to −609.7; P =.001). Being male (odds ratio [OR], 0.11; 95% CI, 0.01 to 0.93; P =.04) and being on anti-CD20 therapy (OR, 0.16; 95% CI, 0.03 to 0.70; P =.016) were associated with nonresponse. Conclusions Overall, most HSCT recipients had high SARS-CoV-2 antibody responses. More vaccine doses improved the magnitude of immune responses. Anti-S IgG monitoring may be useful for identifying attenuated vaccine-induced responses. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. 2098. Cytomegalovirus (CMV) Infection Following Hematopoietic Cell Transplantation (HCT) with Post-transplant Cyclophosphamide (PTCy): Outcomes in Haploidentical versus Matched or Mismatched Unrelated Donor (MUD/MMURD) Allografts

Author

Little, Jessica S, primary, Ni, Jian, additional, Shapiro, Roman M, additional, Romee, Rizwan, additional, Soiffer, Robert J, additional, Sherman, Amy C, additional, Ho, Vincent T T, additional, and Issa, Nicolas C, additional

Published
2022
Full Text
View/download PDF

24. 733. Letermovir treatment for refractory or resistant cytomegalovirus infection or disease with concurrent organ dysfunction: an interim analysis of a Phase 2 open label study.

Author

Gonzalez-Bocco, Isabel H, primary, Cheng, Matthew, additional, Aleissa, Muneerah M, additional, Arbona, Esther I, additional, Chen, Kaiwen, additional, Zhou, Eric, additional, Beluch, Katherine, additional, Cho, Alyssa, additional, Burchett, Sandra, additional, Hammond, Sarah P, additional, Issa, Nicolas C, additional, Sherman, Amy C, additional, and Marty, Francisco M, additional

Published
2022
Full Text
View/download PDF

27. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses

Author

Branche, Angela R., Rouphael, Nadine G., Diemert, David J., Falsey, Ann R., Losada, Cecilia, Baden, Lindsey R., Frey, Sharon E., Whitaker, Jennifer A., Little, Susan J., Anderson, Evan J., Walter, Emmanuel B., Novak, Richard M., Rupp, Richard, Jackson, Lisa A., Babu, Tara M., Kottkamp, Angelica C., Luetkemeyer, Anne F., Immergluck, Lilly C., Presti, Rachel M., Bäcker, Martín, Winokur, Patricia L., Mahgoub, Siham M., Goepfert, Paul A., Fusco, Dahlene N., Malkin, Elissa, Bethony, Jeffrey M., Walsh, Edward E., Graciaa, Daniel S., Samaha, Hady, Sherman, Amy C., Walsh, Stephen R., Abate, Getahun, Oikonomopoulou, Zacharoula, El Sahly, Hana M., Martin, Thomas C.S., Rostad, Christina A., Smith, Michael J., Ladner, Benjamin G., Porterfield, Laura, Dunstan, Maya, Wald, Anna, Davis, Tamia, Atmar, Robert L., Mulligan, Mark J., Lyke, Kirsten E., Posavad, Christine M., Meagher, Megan A., Stephens, David S., Neuzil, Kathleen M., Abebe, Kuleni, Hill, Heather, Albert, Jim, Lewis, Teri C., Giebeig, Lisa A., Eaton, Amanda, Netzl, Antonia, Wilks, Samuel H., Türeli, Sina, Makhene, Mamodikoe, Crandon, Sonja, Lee, Marina, Nayak, Seema U., Montefiori, David C., Makowski, Mat, Smith, Derek J., Roberts, Paul C., and Beigel, John H.

Subjects
Article
Abstract

BackgroundProtection from SARS-CoV-2 vaccines wanes over time and is compounded by emerging variants including Omicron subvariants. This study evaluated safety and immunogenicity of SARS-CoV-2 variant vaccines.MethodsThis phase 2 open-label, randomized trial enrolled healthy adults previously vaccinated with a SARS-CoV-2 primary series and a single boost. Eligible participants were randomized to one of six Moderna COVID19 mRNA vaccine arms (50µg dose): Prototype (mRNA-1273), Omicron BA.1+Beta (1 or 2 doses), Omicron BA.1+Delta, Omicron BA.1 monovalent, and Omicron BA.1+Prototype. Neutralization antibody titers (ID50) were assessed for D614G, Delta, Beta and Omicron BA.1 variants and Omicron BA.2.12.1 and BA.4/BA.5 subvariants 15 days after vaccination.ResultsFrom March 30 to May 6, 2022, 597 participants were randomized and vaccinated. Median age was 53 years, and 20% had a prior SARS-CoV-2 infection. All vaccines were safe and well-tolerated. Day 15 geometric mean titers (GMT) against D614G were similar across arms and ages, and higher with prior infection. For uninfected participants, Day 15 Omicron BA.1 GMTs were similar across Omicron-containing vaccine arms (3724-4561) and higher than Prototype (1,997 [95%CI:1,482-2,692]). The Omicron BA.1 monovalent and Omicron BA.1+Prototype vaccines induced a geometric mean ratio (GMR) to Prototype for Omicron BA.1 of 2.03 (97.5%CI:1.37-3.00) and 1.56 (97.5%CI:1.06-2.31), respectively. A subset of samples from uninfected participants in four arms were also tested in a different laboratory at Day 15 for neutralizing antibody titers to D614G and Omicron subvariants BA.1, BA.2.12.2 and BA.4/BA.5. Omicron BA.4/BA.5 GMTs were approximately one third BA.1 GMTs (Prototype 517 [95%CI:324-826] vs. 1503 [95%CI:949-2381]; Omicron BA.1+Beta 628 [95%CI:367-1,074] vs. 2125 [95%CI:1139-3965]; Omicron BA.1+Delta 765 [95%CI:443-1,322] vs. 2242 [95%CI:1218-4128] and Omicron BA.1+Prototype 635 [95%CI:447-903] vs. 1972 [95%CI:1337-2907).ConclusionsHigher Omicron BA.1 titers were observed with Omicron-containing vaccines compared to Prototype vaccine and titers against Omicron BA.4/BA.5 were lower than against BA.1 for all candidate vaccines.Clinicaltrials.govNCT05289037

Published
2022

28. Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies

Author

Sherman, Amy C, primary, Crombie, Jennifer L, additional, Cheng, ChiAn, additional, Desjardins, Michaël, additional, Zhou, Guohai, additional, Ometoruwa, Omolola, additional, Rooks, Rebecca, additional, Senussi, Yasmeen, additional, McDonough, Mikaela, additional, Guerrero, Liliana I, additional, Kupelian, John, additional, Doss-Gollin, Simon, additional, Smolen, Kinga K, additional, van Haren, Simon D, additional, Armand, Philippe, additional, Levy, Ofer, additional, Walt, David R, additional, Baden, Lindsey R, additional, and Issa, Nicolas C, additional

Published
2022
Full Text
View/download PDF

30. The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients

Author

Tolan, Nicole V., primary, Sherman, Amy C., additional, Zhou, Guohai, additional, Nabel, Katherine G., additional, Desjardins, Michaël, additional, Melanson, Stacy, additional, Kanjilal, Sanjat, additional, Moheed, Serina, additional, Kupelian, John, additional, Kaufman, Richard M., additional, Ryan, Edward T., additional, LaRocque, Regina C., additional, Branda, John A., additional, Dighe, Anand S., additional, Abraham, Jonathan, additional, Baden, Lindsey R., additional, Charles, Richelle C., additional, and Turbett, Sarah E., additional

Published
2022
Full Text
View/download PDF

31. Precision Vaccines: Lessons Learned From the Coronavirus Pandemic

Author

Angelidou, Asimenia, primary, Evans, Jay, additional, Idoko, Olubukola, additional, Levy, Ofer, additional, Lewis, Nicole Pignatiello, additional, Nanishi, Etsuro, additional, Odumade, Oludare A, additional, Ozonoff, Al, additional, Plotkin, Stanley, additional, Sherman, Amy C, additional, van Haren, Simon D, additional, and Weitzman, Elissa R, additional

Published
2022
Full Text
View/download PDF

35. Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study

Author

Howard-Anderson, Jessica R., primary, Adams, Carly, additional, Dube, William C., additional, Smith, Teresa C., additional, Sherman, Amy C., additional, Edupuganti, Neena, additional, Mendez, Minerva, additional, Chea, Nora, additional, Magill, Shelley S., additional, Espinoza, Daniel O., additional, Zhu, Yerun, additional, Phadke, Varun K., additional, Edupuganti, Srilatha, additional, Steinberg, James P., additional, Lopman, Benjamin A., additional, Jacob, Jesse T., additional, Fridkin, Scott K., additional, and Collins, Matthew H., additional

Published
2022
Full Text
View/download PDF

36. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice

Author

Nanishi, Etsuro, primary, Borriello, Francesco, additional, O’Meara, Timothy R., additional, McGrath, Marisa E., additional, Saito, Yoshine, additional, Haupt, Robert E., additional, Seo, Hyuk-Soo, additional, van Haren, Simon D., additional, Cavazzoni, Cecilia B., additional, Brook, Byron, additional, Barman, Soumik, additional, Chen, Jing, additional, Diray-Arce, Joann, additional, Doss-Gollin, Simon, additional, De Leon, Maria, additional, Prevost-Reilly, Alejandra, additional, Chew, Katherine, additional, Menon, Manisha, additional, Song, Kijun, additional, Xu, Andrew Z., additional, Caradonna, Timothy M., additional, Feldman, Jared, additional, Hauser, Blake M., additional, Schmidt, Aaron G., additional, Sherman, Amy C., additional, Baden, Lindsey R., additional, Ernst, Robert K., additional, Dillen, Carly, additional, Weston, Stuart M., additional, Johnson, Robert M., additional, Hammond, Holly L., additional, Mayer, Romana, additional, Burke, Allen, additional, Bottazzi, Maria E., additional, Hotez, Peter J., additional, Strych, Ulrich, additional, Chang, Aiquan, additional, Yu, Jingyou, additional, Sage, Peter T., additional, Barouch, Dan H., additional, Dhe-Paganon, Sirano, additional, Zanoni, Ivan, additional, Ozonoff, Al, additional, Frieman, Matthew B., additional, Levy, Ofer, additional, and Dowling, David J., additional

Published
2022
Full Text
View/download PDF

37. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain

Author

Nabel, Katherine G., primary, Clark, Sarah A., additional, Shankar, Sundaresh, additional, Pan, Junhua, additional, Clark, Lars E., additional, Yang, Pan, additional, Coscia, Adrian, additional, McKay, Lindsay G. A., additional, Varnum, Haley H., additional, Brusic, Vesna, additional, Tolan, Nicole V., additional, Zhou, Guohai, additional, Desjardins, Michaël, additional, Turbett, Sarah E., additional, Kanjilal, Sanjat, additional, Sherman, Amy C., additional, Dighe, Anand, additional, LaRocque, Regina C., additional, Ryan, Edward T., additional, Tylek, Casey, additional, Cohen-Solal, Joel F., additional, Darcy, Anhdao T., additional, Tavella, Davide, additional, Clabbers, Anca, additional, Fan, Yao, additional, Griffiths, Anthony, additional, Correia, Ivan R., additional, Seagal, Jane, additional, Baden, Lindsey R., additional, Charles, Richelle C., additional, and Abraham, Jonathan, additional

Published
2022
Full Text
View/download PDF

39. Application of SARS-CoV-2 Serology to Address Public Health Priorities

Author

Sherman, Amy C., primary, Smith, Teresa, additional, Zhu, Yerun, additional, Taibl, Kaitlin, additional, Howard-Anderson, Jessica, additional, Landay, Taylor, additional, Pisanic, Nora, additional, Kleinhenz, Jennifer, additional, Simon, Trevor W., additional, Espinoza, Daniel, additional, Edupuganti, Neena, additional, Hammond, Skyler, additional, Rouphael, Nadine, additional, Shen, Huifeng, additional, Fairley, Jessica K., additional, Edupuganti, Srilatha, additional, Cardona-Ospina, Jaime A., additional, Rodriguez-Morales, Alfonso J., additional, Premkumar, Lakshmanane, additional, Wrammert, Jens, additional, Tarleton, Rick, additional, Fridkin, Scott, additional, Heaney, Christopher D., additional, Scherer, Erin M., additional, and Collins, Matthew H., additional

Published
2021
Full Text
View/download PDF

40. Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity

Author

Sherman, Amy C, primary, Desjardins, Michaël, additional, Cheng, Chi An, additional, Bausk, Bruce, additional, Izaguirre, Natalie, additional, Zhou, Guohai, additional, Krauss, Jonathan, additional, Tolan, Nicole, additional, Walt, David R, additional, Soiffer, Robert, additional, Ho, Vincent T, additional, Issa, Nicolas C, additional, and Baden, Lindsey R, additional

Published
2021
Full Text
View/download PDF

41. 100. Safety Analysis of Live-Attenuated Measles, Mumps, Rubella Vaccine Among Hematopoietic Cell Transplant Recipients Vaccinated Within Two Years of Transplant

Author

Mitre, Xhoi, primary, Feeley, Monica, additional, Sherman, Amy C, additional, Walsh, Stephen R, additional, Cheng, Matthew, additional, Kanjilal, Sanjat, additional, Ho, Vincent T, additional, Baden, Lindsey R, additional, Issa, Nicolas C, additional, and Desjardins, Michaël, additional

Published
2021
Full Text
View/download PDF

42. 996. CD4+ T-Cell Lymphopenia Associated with Frequent Plateletpheresis in Healthy Donors

Author

Cunningham, Phoebe H, primary, Mitre, Xhoi, additional, Pierre, Djenane, additional, Montesano, Christina, additional, Woods, Tenaizus, additional, Oganezova, Karina, additional, Krauss, Jonathan H, additional, Von, Salena S, additional, Kupelian, John A, additional, Gothing, Jon A, additional, Jane, Kleinjan, additional, Caldara, Lise Ann, additional, Sherman, Amy C, additional, Walsh, Stephen R, additional, Kaufman, Richard M, additional, Baden, Lindsey R, additional, and Desjardins, Michaël, additional

Published
2021
Full Text
View/download PDF

43. 24. Longitudinal Assessment of Immune Responses to COVID-19 Vaccines in Solid Organ Transplant Recipients

Author

Powell, Megan, primary, Sherman, Amy C, additional, Klopfer, Julia, additional, Desjardins, Michaël, additional, Cheng, Chi-An, additional, Senussi, Yasmeen, additional, Ratnaparkhi, Saee, additional, Mitre, Xhoi, additional, Feeley, Monica, additional, Avila Paz, Andres A, additional, Kim, Andy J, additional, Rutherford, Henry, additional, Cauley, Jessica, additional, Kim, Austin, additional, Chang, Jun Bai Park, additional, Liakos, Alexis, additional, Woolley, Ann E, additional, Walt, David, additional, and Baden, Lindsey R, additional

Published
2021
Full Text
View/download PDF

44. 586. Immunogenicity of COVID-19 mRNA Vaccines in Patients with Lymphoid Malignancies

Author

Izaguirre, Natalie E, primary, Sherman, Amy C, additional, Crombie, Jennifer, additional, Desjardins, Michaël, additional, Cheng, Chi-An, additional, Gilboa, Tal, additional, Powell, Megan, additional, Bausk, Bruce P, additional, Abasciano, Noah, additional, Baker, Peter, additional, McDonough, Mikaela, additional, Armand, Philippe, additional, Walt, David, additional, Issa, Nicolas C, additional, and Baden, Lindsey R, additional

Published
2021
Full Text
View/download PDF

45. 25. Immunogenicity and Reactogenicity of COVID-19 mRNA Vaccines in Allogeneic Stem Cell Transplant Recipients

Author

Bausk, Bruce P, primary, Sherman, Amy C, additional, Desjardins, Michaël, additional, Izaguirre, Natalie E, additional, Cheng, Chi-An, additional, Powell, Megan, additional, Senussi, Yasmeen, additional, Gilboa, Tal, additional, Krauss, Jonathan H, additional, Dirr, Bonnie, additional, Power, Elyssa, additional, Joyce, Amy, additional, Stewart, Lisa, additional, Ometoruwa, Omolola, additional, Novack, Lewis A, additional, Evans, Bethany, additional, Woods, Tenaizus, additional, Tong, Alexandra, additional, Walt, David, additional, Soiffer, Robert, additional, Ho, Vincent T, additional, Issa, Nicolas C, additional, and Baden, Lindsey R, additional

Published
2021
Full Text
View/download PDF

46. Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies

Author

Crombie, Jennifer L., Sherman, Amy C., Cheng, Chi-An, Ryan, Christine E., Zon, Rebecca, Desjardins, Michaël, Baker, Peter, McDonough, Mikaela, Izaguirre, Natalie, Bausk, Bruce, Krauss, Jonathan, Gilboa, Tal, Senussi, Yasmeen, Walt, David R., Davids, Matthew S., Brown, Jennifer R., Armand, Philippe, Baden, Lindsey R., and Issa, Nicolas

Published
2021
Full Text
View/download PDF

47. Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients

Author

Ogata, Alana F, Cheng, Chi-An, Desjardins, Michaël, Senussi, Yasmeen, Sherman, Amy C, Powell, Megan, Novack, Lewis, Von, Salena, Li, Xiaofang, Baden, Lindsey R, and Walt, David R

Subjects
COVID-19 Vaccines, SARS-CoV-2, viruses, Brief Report, fungi, COVID-19, spike, Antibodies, Viral, immune responses, respiratory tract diseases, Immunoglobulin A, body regions, AcademicSubjects/MED00290, mRNA vaccine, SARS-CoV-2 antigens, Spike Glycoprotein, Coronavirus, Humans, skin and connective tissue diseases, 2019-nCoV Vaccine mRNA-1273
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. Eleven of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day 1 after first vaccine injection. Clearance of detectable SARS-CoV-2 protein correlated with production of immunoglobulin G (IgG) and immunoglobulin A (IgA).

Published
2021

49. Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity.

Author

Sherman, Amy C, Desjardins, Michaël, Cheng, Chi An, Bausk, Bruce, Izaguirre, Natalie, Zhou, Guohai, Krauss, Jonathan, Tolan, Nicole, Walt, David R, Soiffer, Robert, Ho, Vincent T, Issa, Nicolas C, and Baden, Lindsey R

Subjects
*COVID-19 vaccines, *SERODIAGNOSIS, *PATIENTS, *TREATMENT effectiveness, *MESSENGER RNA, *DESCRIPTIVE statistics, *HEMATOPOIETIC stem cell transplantation, *TRANSPLANTATION of organs, tissues, etc.
Abstract

The severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine–induced humoral response and reactogenicity profile are described in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Findings showed that 75.0% (by Simoa assay) or 80.0% (by Roche assay) of the HSCT cohort had a positive antibody response on series completion, compared with 100% in the healthy cohort. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity

Author

Nanishi, Etsuro, primary, Borriello, Francesco, additional, O’Meara, Timothy R., additional, McGrath, Marisa E., additional, Saito, Yoshine, additional, Haupt, Robert E., additional, Seo, Hyuk-Soo, additional, van Haren, Simon D., additional, Brook, Byron, additional, Chen, Jing, additional, Diray-Arce, Joann, additional, Doss-Gollin, Simon, additional, Leon, Maria De, additional, Chew, Katherine, additional, Menon, Manisha, additional, Song, Kijun, additional, Xu, Andrew Z., additional, Caradonna, Timothy M., additional, Feldman, Jared, additional, Hauser, Blake M., additional, Schmidt, Aaron G., additional, Sherman, Amy C., additional, Baden, Lindsey R., additional, Ernst, Robert K., additional, Dillen, Carly, additional, Weston, Stuart M., additional, Johnson, Robert M., additional, Hammond, Holly L., additional, Mayer, Romana, additional, Burke, Allen, additional, Bottazzi, Maria E., additional, Hotez, Peter J., additional, Strych, Ulrich, additional, Chang, Aiquan, additional, Yu, Jingyou, additional, Barouch, Dan H., additional, Dhe-Paganon, Sirano, additional, Zanoni, Ivan, additional, Ozonoff, Al, additional, Frieman, Matthew B., additional, Levy, Ofer, additional, and Dowling, David J., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results